CRO Services

Live cell + AI platform

Pushing the boundaries of precision medicine with live cell analysis and AI to support personalized treatments.

Live-cell-based
CRO services

AI-Driven
CRO services

Live-cell-based CRO ServiceS

Supporting precise development of novel drugs

We have developed the proprietary method for analyzing ex vivo drug sensitivities (DS) of anticancer drugs.

임프리메드는 항암제에 대한 체외 약물 감수성 분석을 위한 독점적인 방법을 개발하였습니다.

Together with the functional and/or genomic characterization of the cancer cells, the DS results can be used in any of the following ways:

Live-cell-based CRO services we offer

Service Options
Drug Development Stage

Results

Process

01.
Immunophenotyping & genotyping
01. Immunophenotyping & genotyping
  • Drug screening
  • Pre-clinical
  • Phases I, II, and III
  • Flow cytometry
  • PCR for antigen receptor rearrangements (PARR)
  • Gene mutations or expressions
  • Immunophenotyping + genotyping report including prognostic information
ImpriMed offers immunophenotyping services
Immunophenotyping
Assay
02.
Ex vivo drug sensitivity test
02. Ex vivo drug sensitivity test
  • Drug screening
  • Pre-clinical
  • Phases I, II, and III
  • Ex vivo sensitivity of the new drug compound(s) on patients’ live cancer cells
  • AI-driven drug response prediction scores for conventional drugs
  • Time-course efficacy and prognosis prediction for a gold standard combinatorial protocol
ImpriMed offers immunophenotyping services
Immunophenotyping
Assay
ImpriMed offers drug sensitivity tests
Drug Sensitivity Assay
03.
Responder vs. Non-responder profiling
03. Responder vs. Non-responder
  • Pre-clinical
  • Phases I
  • Refined inclusion criteria for clinical trials based on responding patients’:
  • Immune subtypes (antigen expression profiles using 10+ antibodies)
  • Ex vivo responses against the new drug compound(s) and the drug panel
  • Naive/relapse and signalment information, etc.
ImpriMed offers immunophenotyping services
Immunophenotyping
Assay
ImpriMed offers drug sensitivity tests
Drug Sensitivity Assay
ImpriMed offers data analytics
Data Analysis (Population-based)
04.
Identification of synergistic combination
04. Identification of synergistic combination
  • Pre-clinical
  • Phases I
  • Live-cell based, ex vivo population study data investigate new drug combinations between the existing drugs and the new drug compound(s)
  • Mechanism of action analysis
  • New target(s) identification
ImpriMed offers immunophenotyping services
Immunophenotyping
Assay
ImpriMed offers drug sensitivity tests
Drug Sensitivity Assay
ImpriMed offers data analytics
Data Analysis (Population-based)
05.
Response predictions for individual patients
05. Response predictions for individual patients
  • Phases II and III
  • All the above results throughout the life of the clinical study or trial
  • Development of a companion diagnostic AI model that predicts clinical response and prognosis of the new drug compound
  • Adding the new drug(s) to the drug panel in ImpriMed’s commercial services
ImpriMed offers immunophenotyping services
Immunophenotyping
Assay
ImpriMed offers drug sensitivity tests
Drug Sensitivity Assay
ImpriMed provides AI-driven personalized medicine services
Model Development
& Data Analysis
(Personalized)

We offer a suite of customizable CRO services for drug candidates targeting human acute myeloid leukemia, non-Hodgkin lymphoma, or blood cancers in companion animals.

Develop, validate, and commercialize machine learning models trained with your datasets

AI-Driven CRO ServiceS

Empower your datasets with artificial intelligence

Train machine learning models using your datasets and validate their performance using our accredited protocol/service

Develop machine learning models of your interest

ImpriMed develops machine learning models based on your unique needs and available datasets.

1

Broad Expertise Across Species and Diseases
ImpriMed has successfully developed machine learning models for diverse species and disease types including:

  • Human / canine / feline lymphomas
  • Acute myeloid leukemia (AML), lymphoblastic leukemia (ALL)
  • Multiple myeloma
  • Pancreatic cancer
  • Rheumatoid arthritis

2

Expertise in Real-World Data
We're experienced in utilizing real-world evidence datasets from multitude of hospitals, covering:

  • Genetic datasets (raw sequencing results, annotated files)
  • Flow cytometry analysis results (FSC, SSC, antigen expression levels)
  • Drug sensitivity analysis results (IC50, AUC, Emax, DSS, dDSS)

3

Certified Excellence
Our development and production processes are GMP-accredited for development and production of AI-based software medical devices.

4

Recognized and Published
Our results have been published in SCI(E) journals, such as npj Precision Oncology, and presented at leading international conferences, including the American Society of Hematology.

AI-Driven CRO services we offer

Service Options

Results

Process

01.
Statistical analysis of your datasets
01. Immunophenotyping & genotyping
  • Hypothesis testing
  • Survival analysis
  • Univariate, multivariate analysis
  • Comparative analysis
Statistical Analysis
02.
Machine learning model development
02. Ex vivo drug sensitivity test
  • Includes statistical analysis
  • Preprocessing of the datasets
  • Development of machine learning models
  • Cross-fold validation of the models
Statistical Analysis
ML Model Development
03.
Validation of machine learning models
03. Responder vs. Non-responder
  • Includes statistical analysis
  • Independent validation of your machine learning model performance
  • Perform test using independent datasets from other institutions
Statistical Analysis
ML Model Development
ML Model Testing
04.
Commercialization of your machine learning model
05. Response predictions for individual patients
  • Includes validation of the ML model(s)
  • Have your ML models be commercially available
Statistical Analysis
ML Model Development
ML Model Testing
Productionization
Let's talk

Request a Proposal

Are you interested in receiving a proposal from ImpriMed? Leave us a message and we will get back to you shortly.